A176 SOFOSBUVIR/VELPATASVIR-BASED REGIMENS ARE ASSOCIATED WITH EXCELLENT EFFICACY AND A SIGNIFICANT IMPROVEMENT OF PATIENTS-REPORTED OUTCOMES ACROSS PATIENT POPULATIONS: FROM NON-CIRRHOTICS TO COMPENSATED CIRRHOTICS TO DECOMPENSATED CIRRHOTICS

AIMS: Our aim was to assess the impact SOF/VEL±ribavirin (RBV) on patient-reported outcomes (PROs) in HCV patients with and without decompensated cirrhosis. METHODS: Four PRO questionnaires (SF-36, CLDQ-HCV, FACIT-F, WPAI:HCV) were collected in 4 phase 3 trials of SOF/VEL (ASTRAL-1,2, 3 and 4). The...

詳細記述

保存先:
書誌詳細
出版年:J Can Assoc Gastroenterol
主要な著者: Younossi, Z M, Stepanova, M, Feld, J, Zeuzem, S, Sulkowski, M S, Foster, G R, Mangia, A, Charlton, M, O’Leary, J, Curry, M, Nader, F, Henry, L, Hunt, S
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2018
主題:
Poster Presentations
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6507918/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy008.177
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料